Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

67.66 -0.54 (-0.79%)
Streaming Delayed Price Updated: 11:51 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
81 82 Next >
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable. 
Via Chartmill
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
Via Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
These two players are set on finding the next big therapeutic modality. 
Via The Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. The Dow Jones Industrial Average hit a record high Friday as investors... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
Inflation data supports another 0.5% interest rate cut in November, says RSM US LLP Chief Economist Joseph Brusuelas. S&P 500 hits all-time high. Brainard supports China EV ban. Meta Platforms unveils... 
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected. 
Via Investor's Business Daily
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
The thrust of the company's long-term strategy is becoming clearer. 
Via The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. 
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Even the mighty Novo Nordisk can't hold a candle to its peer in this area. 
Via The Motley Fool
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected... 
Via Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock. 
Via The Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
If understood an applied correctly, technical analysis is the study or investor and trader psychology. The chart of NVO shows this. 
Via Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in patients with opioid use disorder. Findings highlight the need for more research... 
Via Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose. 
Via Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line. 
Via Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from Congress. 
Via Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Last week, another Novo executive indicated that Ozempic would "very likely" be included in the 2027 list. 
Via Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished. 
Via The Motley Fool
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company's diversified pipeline. 
Via Benzinga
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.